← All trials
NCT06632912
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2024
- Primary completion
- May 31, 2025
- Completion date
- Jun 30, 2030
- First posted
- Oct 9, 2024
- Last posted
- Oct 9, 2024
- Enrollment
- 1800
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Vaccine and Serum Institute, ChinaLead sponsor
- Chengdu Institute of Biological Products Co.,Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.